Mauro Pettorruso

Dr. Mauro Pettorruso

Department of Neuroscience, Imaging and Clinical Sciences, "G. d' Annunzio" University, Chieti, Italy
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2019 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
HEHamed Ekhtiari
Hamed Ekhtiari
HTHosna Tavakoli
Hosna Tavakoli
GAGiovanni Addolorato
Giovanni Addolorato
CBChris Baeken
Chris Baeken
ABAntonello Bonci
Antonello Bonci
CHColleen A. Hanlon
Colleen A. Hanlon

16 March 2018 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Giovanni MartinottiGiovanni Martinotti
Giovanni Martinotti
RSRita Santacroce
Rita Santacroce
Mauro PettorrusoMauro Pettorruso
Mauro Pettorruso
CMChiara Montemitro
Chiara Montemitro
MSMaria Chiara Spano
Maria Chiara Spano
ALArturo G. Lerner
Arturo G. Lerner
Hallucinogen Persisting Perception Disorder (HPPD) is a rare, and therefore, poorly understood condition linked to hallucinogenic drugs consumption. The prevalence of this disorder is low; the condition is more often diagnosed in individuals with a history of previous psychological issues or substance misuse, but it can arise in anyone, even after a single exposure to triggering drugs. The aims of the present study are to review all the original studies about HPPD in order to evaluate the following: (1) the possible suggested etiologies; (2) the possible hallucinogens involved in HPPD induction; (3) the clinical features of both HPPD I and II; (4) the possible psychiatric comorbidities; and (5) the available and potential therapeutic strategies. We searched PubMed to identify original studies about psychedelics and Hallucinogen Persisting Perception Disorder (HPPD). Our research yielded a total of 45 papers, which have been analyzed and tabled to provide readers with the most updated and comprehensive literature review about the clinical features and treatment options for HPPD.

1 July 2017 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
LMLorenzo Moccia
Lorenzo Moccia
Mauro PettorrusoMauro Pettorruso
Mauro Pettorruso
FCFranco De Crescenzo
Franco De Crescenzo
LRLuisa De Risio
Luisa De Risio
LNLuigi di Nuzzo
Luigi di Nuzzo
MNMarco Di Nicola
Marco Di Nicola

10 November 2020 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
LRLuisa De Risio
Luisa De Risio
MBMarta Borgi
Marta Borgi
Mauro PettorrusoMauro Pettorruso
Mauro Pettorruso
AMAndrea Miuli
Andrea Miuli
AOAngela Maria Ottomana
Angela Maria Ottomana
FZFrancesca Zoratto
Francesca Zoratto
Repetitive transcranial magnetic stimulation (rTMS) has gained growing interest for the treatment of major depression (MDD) and treatment-resistant depression (TRD). Most knowledge on rTMS comes from human studies as preclinical application has been problematic. However, recent optimization of rTMS in animal models has laid the foundations for improved translational studies. Preclinical studies have the potential to help identify optimal stimulation protocols and shed light on new neurobiological-based rationales for rTMS use. To assess existing evidence regarding rTMS effects on depressive-like symptoms in rodent models, we conducted a comprehensive literature search in accordance with PRISMA guidelines (PROSPERO registration number: CRD42019157549). In addition, we conducted a meta-analysis to determine rTMS efficacy, performing subgroup analyses to examine the impact of different experimental models and neuromodulation parameters. Assessment of the depressive-like phenotype was quite homogeneous whilst rTMS parameters among the 23 included studies varied considerably. Most studies used a stress-induced model. Overall, results show a largely beneficial effect of active rTMS compared to sham stimulation, as reflected in the statistically significant recovery of both helplessness (SDM 1.34 [1.02;1.66]) and anhedonic (SDM 1.87 [1.02;2.72]) profiles. Improvement of the depressive-like phenotype was obtained in all included models and independently of rTMS frequency. Nonetheless, these results have limited predictive value for TRD patients as only antidepressant-sensitive models were used. Extending rTMS studies to other MDD models, corresponding to distinct endophenotypes, and to TRD models is therefore crucial to test rTMS efficacy and to develop cost-effective protocols, with the potential of yielding faster clinical responses in MDD and TRD.

1 March 2015 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
MNMarco Di Nicola
Marco Di Nicola
DTDaniela Tedeschi
Daniela Tedeschi
LRLuisa De Risio
Luisa De Risio
Mauro PettorrusoMauro Pettorruso
Mauro Pettorruso
GMGiovanni Martinotti
Giovanni Martinotti
LJLuigi Janiri
Luigi Janiri

1 July 2020 in Psychiatry Research
Verified
Journal Article
Closed access
Mauro PettorrusoMauro Pettorruso
Mauro Pettorruso
SVStephanie Valle
Stephanie Valle
ECElizabeth Cavic
Elizabeth Cavic
GMGiovanni Martinotti
Giovanni Martinotti
MGMassimo di Giannantonio
Massimo di Giannantonio
JGJon E. Grant
Jon E. Grant